Search Result

Isoforms Recommended:	CBP/p300

Results for "

EP300

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (2) Apoptosis (12) Autophagy (5) Bacterial (2) Caspase (1) Cholinesterase (ChE) (1) E3 Ligase Ligand-Linker Conjugates (2) Endogenous Metabolite (1) Epigenetic Reader Domain (48) Ferroptosis (3) HIF/HIF Prolyl-Hydroxylase (3) Histone Acetyltransferase (74) Histone Demethylase (1) Influenza Virus (3) Keap1-Nrf2 (3) Ligands for Target Protein for PROTAC (6) MDM-2/p53 (2) Mitophagy (3) Molecular Glues (1) PARP (1) PROTACs (14) Small Interfering RNA (siRNA) (3) STAT (1) Toll-like Receptor (TLR) (2) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (103) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (5)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

113

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS04405

EP300 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
EP300 Human Pre-designed siRNA Set A contains three designed siRNAs for EP300 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EP300 Human Pre-designed siRNA Set A EP300 Human Pre-designed siRNA Set A

HY-RS04406

Ep300 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ep300 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ep300 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ep300 Mouse Pre-designed siRNA Set A Ep300 Mouse Pre-designed siRNA Set A

HY-RS04407

Ep300 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ep300 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ep300 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ep300 Rat Pre-designed siRNA Set A Ep300 Rat Pre-designed siRNA Set A

HY-160260

EP300/CBP-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
EP300/CBP-IN-1 (compound 172) is a potent *EP300/CBP* inhibitor with IC₅₀s of 2.3 nM and 2.1 nM for CBP BRD and EP300 BRD, respectively. EP300/CBP-IN-1 has the inhibitory effect on the proliferation of prostate cancer CWR22RV1 cells .

HY-160261S

EP300/CBP-IN-2	Epigenetic Reader Domain	Cancer
EP300/CBP-IN-2 is a potent *EP300/CBP* inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .

HY-128364

Ep300/CREBBP-IN-3	Histone Acetyltransferase	Cancer
Ep300/CREBBP-IN-3 (Example 61) is a potent *Ep300* and CREBBP inhibitor with IC₅₀s of 0.056 and 0.095 μM, respectively. Ep300/CREBBP-IN-3 can be used for the research of cancer .

HY-128367

Ep300/CREBBP-IN-4	Histone Acetyltransferase	Cancer
Ep300/CREBBP-IN-4 (Example 56) is a potent *Ep300* and CREBBP inhibitor with IC₅₀s of 0.024 and 0.064 μM, respectively. Ep300/CREBBP-IN-4 can be used for the research of cancer .

HY-128363

Ep300/CREBBP-IN-2	Histone Acetyltransferase	Cancer
Ep300/CREBBP-IN-2 (Example 73) is a potent and orally active *Ep300* and CREBBP inhibitor with IC₅₀s of 0.052 and 0.148 μM, respectively. Ep300/CREBBP-IN-2 can be used for the research of cancer .

HY-128362

Ep300/CREBBP-IN-8	Histone Acetyltransferase	Cancer
Ep300/CREBBP-IN-8 (Example 37) is a potent and orally active *Ep300* and CREBBP inhibitor with IC₅₀s of 0.014 and 0.018 μM, respectively. Ep300/CREBBP-IN-8 can be used for the research of cancer .

HY-161959

EP300/CBP ligand 1	Ligands for Target Protein for PROTAC	Cancer
EP300/CBP ligand 1 is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). EP300/CBP ligand 1 can be used for synthesis dCE-2 (HY-161958) .

HY-161960

EP300/CBP ligand 2	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
EP300/CBP ligand 2 (compound S19) is a ligand targeting the bromodomain of CREB binding protein (CBP) and E1A-associated protein (EP300). EP300/CBP ligand 2 can be used as a target protein ligand in the PROTAC structure, and can be coupled to the E3 ubiquitin ligase ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, EP300/CBP ligand 2 can be coupled with the conjugate (E3 ubiquitin enzyme ligand + Linker) Thalidomide-NH-C10-Boc (HY-161961) to produce the PROTAC molecule dCE-2 (HY-161958) .

HY-164005

*CBP/EP300* bromodomain receptor-IN-1**	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/EP300 bromodomain receptor-IN-1 (Compound 10) is an inhibitor for CBP/EP300 bromodomain receptor, which binds to proteins having a bromodomain in nanomolar level .

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .

HY-100726

GNE-272 2 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
GNE-272 is a potent and selective *CBP/EP300* inhibitor with IC₅₀ values of 0.02, 0.03 and 13 μM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300 .

HY-128761

CBP/p300-IN-2	Epigenetic Reader Domain	Cancer
CBP/EP300-IN-2 is an inhibitor of *CBP/EP300* with IC₅₀ values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1 .

HY-143441

CBP/p300-IN-17	Histone Acetyltransferase	Cancer
CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143442

CBP/p300-IN-18	Histone Acetyltransferase	Cancer
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143440

CBP/p300-IN-16	Histone Acetyltransferase	Cancer
CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-145765

JQAD1	PROTACs Histone Acetyltransferase Apoptosis Caspase PARP	Cancer
JQAD1 is a CRBN-dependent PROTAC that selectively targets *EP300* for degradation. JQAD1 suppresses EP300 expression and the H3K27ac modification. JQAD1 induces apoptosis. JQAD1 can be used in research of cancer .

HY-145386

(S,S)-CPI-1612	Others	Cancer
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-136285A

(R,R)-CPI-1612	Others	Cancer
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-100482

CPI-637 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CPI-637 is a selective and potent *CBP/EP300* bromodomain inhibitor with IC₅₀ values of 0.03 μM, 0.051 μM and 11.0 μM for CBP, *EP300* and BRD4 BD-1, respectively, and an EC₅₀ of 0.3 μM for CBP .

HY-143443

DS17701585	Histone Acetyltransferase Histone Demethylase	Cancer
DS17701585 (Compound 11) is a highly selective, orally active *EP300* and CBP inhibitor with IC₅₀ values of 0.040, 0.15, 0.45 and 0.70 µM against CBP, EP300, H3K27 and SOX2. DS17701585 can be used for cancer research .

HY-139861

CBP/p300-IN-14	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of *CBP/EP300* (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-152241

DS-9300	Histone Acetyltransferase	Cancer
DS-9300 is a potent, orally active, selective EP300/CBP HAT inhibitor with an IC₅₀ value of 28 nM. DS-9300 has anticancer activity and can be used in prostate cancer disease research .

HY-161958

dCE-2	PROTACs Histone Acetyltransferase	Cancer
dCE-2 (compound 5) is a PROTAC targeting CREB binding protein (CBP) and E1A-associated protein (EP300), which was developed based on the crystal structure of bromodomain (BRD) inhibitors. dCE-2 is composed of E3 ubiquitin ligase ligand Thalidomide-4-OH (HY-103596) (blue part), PROTAC Linker tert-Butyl 11-aminoundecanoate (HY-130715) (black part) and PROTAC target protein ligand EP300/CBP ligand 2 (HY-161960) (red part), of which the target protein ligand activity control is EP300/CBP ligand 1 (HY-161959), and the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-NH-C10-Boc (HY-161961) ^{[1] ^.}

HY-146445

P300 bromodomain-IN-1	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
P300 bromodomain-IN-1 (Compoun 1u) is a potent p300 (EP300) bromodomain inhibitor with an IC₅₀ of 49 nM. P300 bromodomain-IN-1 suppresses the expression of c-Myc and induces G1/G0 phase arrest and apoptosis in OPM-2 cells .

HY-111422

PLX51107 3 Publications Verification	Epigenetic Reader Domain	Cancer
PLX51107 is a potent and selective BET inhibitor, with K_ds of 1.6, 2.1, 1.7, and 5 nM for BD1 and 5.9, 6.2, 6.1, and 120 nM for BD2 of BRD2, BRD3, BRD4, and BRDT, respectively; PLX51107 also interacts with the bromodomains of CBP and EP300 (K_d, in the 100 nM range).

HY-161961

Thalidomide-NH-C10-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C10-Boc (compound S20) is a conjugate of the E3 ubiquitinase ligand Thalidomide and PROTAC Linker, which can recruit Cereblon ubiquitinase. Thalidomide-NH-C10-Boc can couple the target protein ligand through the PTOTAC Linker to synthesize PROTAC molecules with degradation effects. For example, Thalidomide-NH-C10-Boc can couple with the ligand EP300/CBP ligand 2 (HY-161960) to produce the PROTAC molecule dCE-2 (HY-161958) .

HY-147008

XP-524	Epigenetic Reader Domain	Cancer
XP-524 is a potent BET and *EP300* inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .

HY-151812

CBP/p300-IN-20	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
CBP/p300-IN-20 is a potent and selective *p300/CBP* inhibitor, with a pIC₅₀ of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer .

HY-155229

CBP/p300-IN-21	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-21 (Compound 5d) is a selective *CBP/p300* inhibitor (IC₅₀: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice .

HY-134621

P300-IN-1	Histone Acetyltransferase	Cancer
P300-IN-1 (cpd205) is a Histone acetylase p300 inhibitor .

HY-161483

CBP/p300 ligand 3	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). CBP and *p300* are two proteins with histone acetyltransferase (HAT) activity, and CBP and *p300* play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-146277

CBP/p300-IN-19	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .

HY-138536

PROTAC CBP/P300 Degrader-1 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines .

HY-132197

CBP/p300-IN-12	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-146277A

CBP/p300-IN-19 hydrochloride	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-19541

I-CBP112 3 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-139707

Thalidomide-NH-CBP/p300 ligand 2	PROTACs Molecular Glues Epigenetic Reader Domain	Cancer
Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440) .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent *p300/CBP* inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-128876

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-131035

Lys-CoA TFA	Histone Acetyltransferase	Cancer
Lys-CoA TFA is a selective *p300* histone acetyltransferase (HAT) inhibitor (IC₅₀=50-500 nM). Lys-CoA TFA displays >100-fold selectivity for p300 over PCAF (IC₅₀=200 μM). Lys-CoA TFA inhibits p300 HAT activity-dependent transcriptional activation .

HY-138539

CBP/p300 ligand 2	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-161711

CBP/p300 ligand 5	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia .

HY-107455

A-485 50+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485 is a potent and selective catalytic inhibitor of *p300/CBP* with IC₅₀s of 9.8 nM and 2.6 nM for *p300* and CBP histone acetyltransferase (HAT), respectively .

Cat. No.	Product Name	Target	Research Area

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2020

Anacardic Acid 5+ Cited Publications Hydroginkgolic acid; Ginkgolic Acid C15:0	Structural Classification Ginkgoaceae Classification of Application Fields Source classification Plants Ginkgo biloba Monophenols Ketones, Aldehydes, Acids Phenols Anacardium occidentaleL. Disease Research Fields Anacardiaceae Cancer	Histone Acetyltransferase Epigenetic Reader Domain Bacterial
Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of ∼8.5 μM and ∼5 μM, respectively.

HY-N0005

Curcumin Maximum Cited Publications 71 Publications Verification Diferuloylmethane; Natural Yellow 3; Turmeric yellow	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Food Research Microorganisms Sunscreen Phenols Polyphenols Pigments Cosmetic Research Curcuma longa Disease Research Fields Zingiberaceae Cancer	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-107569

Garcinol 1 Publications Verification	Structural Classification Classification of Application Fields Guttiferae Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Garcinia indica	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards acetyl cholinesterase (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀ = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-N2345

Procyanidin B3	Structural Classification Classification of Application Fields Source classification Plants Flavonoids other families Functional Molecules Research of Health Products Phenols Polyphenols Biflavones Disease Research Fields Cancer	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

HY-N2020R

Anacardic Acid (Standard)	Structural Classification Monophenols Ginkgoaceae Ketones, Aldehydes, Acids Source classification Phenols Plants Anacardium occidentaleL. Ginkgo biloba Anacardiaceae	Histone Acetyltransferase Epigenetic Reader Domain Bacterial
Anacardic Acid (Standard) is the analytical standard of Anacardic Acid. This product is intended for research and analytical applications. Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC₅₀s of ～8.5 μM and ～5 μM, respectively.

HY-N0005R

Curcumin (Standard)	Structural Classification Microorganisms Source classification Phenols Polyphenols Plants Curcuma longa Zingiberaceae	Histone Acetyltransferase Epigenetic Reader Domain Keap1-Nrf2 Autophagy Mitophagy Influenza Virus Ferroptosis
Curcumin (Standard) is the analytical standard of Curcumin. This product is intended for research and analytical applications. Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

HY-N2345R

Procyanidin B3 (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Biflavones	Histone Acetyltransferase Toll-like Receptor (TLR) Androgen Receptor
Procyanidin B3 (Standard) is the analytical standard of Procyanidin B3. This product is intended for research and analytical applications. Procyanidin B3 is a natural product with antioxidant activity and oral bioavailability, possessing good blood-brain barrier penetration. Procyanidin B3 is a selective inhibitor of histone acetyltransferase (HAT). By inhibiting p300 HAT-mediated acetylation of the androgen receptor (androgen receptor). Procyanidin B3 alleviates intervertebral disc degeneration (IVDD) by inhibiting the formation of the TLR4/MD-2 complex. Procyanidin B3 can be used in research on prostate cancer and arthritis .

Species:	Human (2)
Tag:	His (1) GST (1)
Source:	Sf9 insect cells (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P702892

	EP300 Protein, Human (His) P300	Human	E. coli

HY-P702963

	EP300 Protein, Human (sf9, GST) P300; p300 HAT; Histone acetyltransferase p300	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0005S

Curcumin-d6
Curcumin-d₆is a deuterium labeled Curcumin (Turmeric yellow). Curcumin (Turmeric yellow) is a natural phenolic compound with diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin is an inhibitor of p300 histone acetylatransferase (HATs) and also shows inhibitory effects on NF-κB and MAPKs.

HY-160261S

EP300/CBP-IN-2
EP300/CBP-IN-2 is a potent *EP300/CBP* inhibitor that has good activity in vivo. EP300/CBP-IN-2 can be used for the research of cancer .

HY-168148S

CZL-046
CZL-046 (compund 29) is an oral *p300* bromodomain inhibitor .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80775

	p300 Antibody EP300; P300; Histone acetyltransferase p300; p300 HAT; E1A-associated protein p300	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	p300 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 264 kDa, targeting to p300. It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.